Schrödinger is the scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical, biotechnology, and materials research.

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.

難溶性薬物の放出メカニズムを解明する – ASD研究の新たなアプローチ | Modelling amorphous solid dispersion (ASD) release mechanisms OCT 15, 2025 | AbbVie と Schrödinger のエキスパートが …

Headquartered in New York City, Schrödinger has multiple offices around the world including the USA, the UK, Germany, India, and Japan.

Jan 9, 2026 · Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and …

We are leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.

Jan 12, 2026 · Schrdinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on …

Nov 12, 2024 · Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties Expanded multi-year software agreement enables …

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

Feb 19, 2026 · Schrödinger デジタル創薬セミナー: Into the Clinic ~計算化学がもたらす創薬プロセスの変貌~ 第11回 強固なコンフォメーションのアンサンブル生成能力、受容体との相互作用を予測す …